Response to Final Office Action dated May 20, 2010

Page 2

CLAIMS

1-35. (canceled)

Please add the following new claims:

36. (new) A compound of formula I

$$R^{1}$$
 R^{0}
 R^{5}
 R^{6}
 R^{7}
 R^{8}
 R^{2}
 R^{3}
 R^{4}
 R^{4}
 R^{10}
 R^{10}
 R^{10}
 R^{10}
 R^{10}
 R^{10}

each of R⁰ or R² independently is hydrogen, C₁-C₈alkyl, haloC₁-C₈alkyl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, C₁-C₈alkoxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclylC₁-C₈alkoxy, unsubstituted or substituted amino, or halogen;

R¹ is hydrogen, C₁-C₈alkyl, haloC₁-C₈alkyl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, C₁-C₈alkoxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclylC₁-C₈alkoxy, unsubstituted or substituted amino, halogen;

 R^3 is C_1 - C_8 alkylsulfinyl, C_1 - C_8 alkylsulfonyl, C_5 - C_{10} arylsulfonyl, or unsubstituted or substituted carbamoyl;

R⁴ is hydrogen;

R⁵ is chloro or bromo;

R⁶ is hydrogen;

each of R⁷ and R⁹ independently is hydrogen, C₁-C₈alkyl, haloC₁-C₈alkyl, unsubstituted or substituted C₅-C₁₀aryl, unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S, C₁-C₈alkoxy, unsubstituted or substituted heterocyclyloxy, unsubstituted or substituted heterocyclylC₁-C₈alkoxy, unsubstituted or substituted amino, halogen, unsubstituted or substituted carbamoyl, or unsubstituted or substituted sulfamoyl;

Inventors: Carlos Garcia-Echeverria et al. International Filing Date: 12 March 2004

Response to Office Action mailed 12 October 2010

Page 3

 R^8 is C_5 - C_{10} aryl; unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S; C_5 - C_{10} aryloxy; unsubstituted or substituted heterocyclyloxy; or unsubstituted or substituted heterocyclyl C_1 - C_8 alkoxy; and

 R^{10} is C_1 - C_8 alkyl, halo C_1 - C_8 alkyl, C_1 - C_8 alkoxy, unsubstituted or substituted heterocyclyl C_1 - C_8 alkoxy, unsubstituted or substituted amino, or halogen; and

A is C;

or salts thereof.

- 37. (new) The compound of claim 36, wherein each of R^0 , R^1 or R^2 is hydrogen.
- 38. (new) The compound of claim 36, wherein R^3 is C_1 - C_8 alkylsulfonyl, C_5 - C_{10} arylsulfonyl or unsubstituted or substituted carbamoyl.
 - 39. (new) The compound of claim 36, wherein R^3 is C_1 - C_8 alkylsulfonyl.
 - 40. (new) The compound of claim 36, wherein R^3 is C_5 - C_{10} ary lsulfonyl.
- 41. (new) The compound of claim 36, wherein R³ is unsubstituted or substituted carbamoyl.
- 42. (new) The compound of claim 36, wherein R⁸ is piperidino, piperazino, N-methylpiperazino, morpholino, phenoxy, 1-methyl-4-piperidyloxy, 3-morpholinopropoxy, 2-morpholinoethoxy or 3-(N-methylpiperazino)-propoxy.
- 43. (new) The compound of claim 36, wherein R⁸ is unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S.
- 44. (new) The compound of claim 36, wherein R^0 , R^1 or R^2 is hydrogen; R^3 is C_1 - C_8 alkylsulfonyl; and R^8 is unsubstituted or substituted 5 or 6 membered heterocyclyl comprising 1 or 2 hetero atoms selected from N, O and S.
- 45. (new) The compound of claim 44, wherein R⁸ is piperidino, piperazino, N-methylpiperazino or morpholino.

Response to Office Action mailed 12 October 2010

PAT032910A-US-PCT International Filing Date: 12 March 2004

Page 4

46. (new) The compound of claim 36, wherein said compound is selected from the group of compounds with the following names or formulae:

2-[5-chloro-2-(2-methoxy-4-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-N-methylbenzamide;

a compound of the formula given in the following table:

ng table:	
Compound No.	Rx
7-1	Lo C
7-2	
	N NH ₂
7-3	
	1

Response to Office Action mailed 12 October 2010

7-4	
7-5	
7-7	>
7-8	→ - - - - - - - - - - - -
7-9	

Response to Office Action mailed 12 October 2010

7-10	
7-11	
7-12	
7-13	H ₂ N O
7-14	

Response to Office Action mailed 12 October 2010

7-17	NH ₂
7-18	NH ₂
7-20	
7-21	
7-25	

Response to Office Action mailed 12 October 2010

Page 8

a compound of the formula given in the following table:

, wherein Rx has one of the meanings


a compound of the formula given in the following table:

Compound	Rx
9-1	N O

Response to Office Action mailed 12 October 2010 Page 9

Response to Office Action mailed 12 October 2010

Page 10



a compound of the formula

, wherein Rx has one of the meanings

given in the following table:

Compound	Rx
10-1	
10-2	

Response to Office Action mailed 12 October 2010

Page 11

a compound of the formula given in the following table:

Compound	Rx
11-1	
11-2	
11-4	

PATO32910A-US-PCT

U.S. Application No.: 10/549,250 Inventors: Carlos Garcia-Echeverria et al. International Filing Date: 12 March 2004

Response to Office Action mailed 12 October 2010

Page 12

a compound of the formula

, wherein Ry has one of the meanings given in

the following table:

Compound	Ry
14-1	N N
14-2	
14-3	NH F
14-5	O F
14-6	

PATCO32910A-US-PCT

U.S. Application No.: 10/549,250 Inventors: Carlos Garcia-Echeverria et al. International Filing Date: 12 March 2004

Response to Office Action mailed 12 October 2010

Page 13

a compound of the formula given in the following table:

Compound	Rx
15-1	
15-2	
15-3	, ;

Response to Office Action mailed 12 October 2010

Page 14

a compound of the formula given in the following table:

, wherein Rx has one of the meanings

a compound of the formula

, wherein Rx has one of the

meanings given in the following table:

Compound	Rx
26-1	
26-2	o Z Z A

Response to Office Action mailed 12 October 2010

26-3	N N N N N N N N N N N N N N N N N N N
26-4	→ → → → → → → → → →
26-5	NH ₂
26-6	ZHOO NAME OF THE PROPERTY OF T
26-7	N Ac

Response to Office Action mailed 12 October 2010

26-8	
26-9	
26-10	
26-11	N N N N N N N N N N N N N N N N N N N

Response to Office Action mailed 12 October 2010 Page 17

Response to Office Action mailed 12 October 2010

26-21	HN N
26-22	N N N N N N N N N N N N N N N N N N N
26-23	
26-24	
26-25	NH NH

Response to Office Action mailed 12 October 2010

Page 19

26-26	
26-27	DE D
26-28	J. J
26-29	

a compound of the formula given in the following table:

Compound	Rx
----------	----

Response to Office Action mailed 12 October 2010 Page 20

27-1	
27-2	
27-3	
27-4	~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
27-5	

International Filing Date: 12 March 2004 Response to Office Action mailed 12 October 2010

Page 21

a compound of the formula given in the following table:

Response to Office Action mailed 12 October 2010

Compound	Rx
28-1	O NH ₂
28-2	OH OH
28-3	
28-4	
28-5	

Response to Office Action mailed 12 October 2010 Page 23

28-6	
28-8	
28-9	
28-10	

Response to Office Action mailed 12 October 2010

28-11	N Ac
28-12	
28-13	
28-14	

Response to Office Action mailed 12 October 2010

28-15	H ₂ N O
28-16	N N N N N N N N N N N N N N N N N N N
28-17	
28-18	
28-19	

Response to Office Action mailed 12 October 2010

28-20	Z Z Z
28-21	NET O
28-22	
28-23	

Response to Office Action mailed 12 October 2010

28-24	
28-25	
28-27	NH ₂
28-28	N H NH ₂

Response to Office Action mailed 12 October 2010

Page 28

a compound of the formula

, wherein Rx has one of the

meanings given in the following table:

Compound	Rx
29-1	o o
29-2	
29-3	, ;

a compound of the formula

, wherein Rx has one of the

meanings given in the following table:

Response to Office Action mailed 12 October 2010

Page 29

Compound	Rx
31-2	
	, ;

a compound of the formula

, wherein Rx has one of the

meanings given in the following table:

Compound	Rx
32-1	\$-2\frac{2}{\qquad \qquad \qqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqq
32-2	·,

Response to Office Action mailed 12 October 2010

Page 30

a compound of the formula the following table:

, wherein Ry has one of the meanings given in

Compound	Ry
34-1	^\sells sells sel
34-3	s s
34-4	
34-6	; and

a compound of the formula given in the following table:

Response to Office Action mailed 12 October 2010

Page 31

Compound	Rx
35-1	.;

or a pharmaceutically acceptable salt thereof.

47. (new) The compound of claim 36, wherein said compound is 2-[5-chloro-2-(2-methoxy-4-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-N-methyl-benzamide, or N^2 -(4-[1,4']Bipiperidinyl-1'-yl-2-methoxy-phenyl)-5-chloro- N^4 -[2-(propane-1-sulfonyl)-phenyl]-pyrimidine-2,4-diamine, or a pharmaceutically acceptable salt thereof.

48. (new) A process for the production of a compound of formula I according to claim 36, comprising reacting a compound of formula II

$$R^{1}$$
 R^{5}
 R^{5}
 R^{6}
 R^{2}
 R^{3}
 R^{4}
(II)

wherein R^0 , R^1 , R^2 , R^3 , R^4 , R^5 , and R^6 are as defined in claim 36, and Y is a leaving group, with a compound of formula III

$$R^7$$
 R^8
 R_{10}
 R^9
 R^{10}
(III)

wherein A, R⁷, R⁸, R⁹ and R¹⁰ are as defined in claim 36;

and, if desired, converting a compound of formula I, wherein the substituents have the meaning as defined in claim 36, into another compound of formula I as defined in claim 36;

U.S. Application No.: 10/549,250

Inventors: Carlos Garcia-Echeverria et al.

International Filing Date: 12 March 2004

Response to Office Action mailed 12 October 2010

Page 32

and recovering the resulting compound of formula I in free from or as a salt, and, when required, converting the compound of formula I obtained in free form into the desired salt, or an obtained salt into the free form.

PAT032910A-US-PC

- 49. (new) A pharmaceutical composition comprising a compound according to claim 36, as active ingredient together with one or more pharmaceutically acceptable diluents or carriers.
- 50. (new) A combination comprising a therapeutically effective amount of a compound according to claim 36 and one or more known drug substances, said further drug substance being useful in the treatment of neoplastic diseases or immune system disorders.
- 51. (new) A method for the treatment of breast tumors in a subject in need thereof which comprises administering an effective amount of a compound according to claim 36 or a pharmaceutical composition comprising same.
- 52. (new) The method of claim 51, wherein said compound is 2-[5-chloro-2-(2-methoxy-4-morpholin-4-yl-phenylamino)-pyrimidin-4-ylamino]-N-methyl-benzamide, or N²-(4-[1,4']Bipiperidinyl-1'-yl-2-methoxy-phenyl)-5-chloro-N⁴-[2-(propane-1-sulfonyl)-phenyl]-pyrimidine-2,4-diamine, or a pharmaceutically acceptable salt thereof.